Success Metrics

Clinical Success Rate
93.8%

Based on 60 completed trials

Completion Rate
94%(60/64)
Active Trials
80(46%)
Results Posted
30%(18 trials)
Terminated
4(2%)

Phase Distribution

Ph phase_3
7
4%
Ph early_phase_1
13
7%
Ph phase_2
81
46%
Ph not_applicable
8
5%
Ph phase_1
64
37%

Phase Distribution

77

Early Stage

81

Mid Stage

7

Late Stage

Phase Distribution173 total trials
Early Phase 1First-in-human
13(7.5%)
Phase 1Safety & dosage
64(37.0%)
Phase 2Efficacy & side effects
81(46.8%)
Phase 3Large-scale testing
7(4.0%)
N/ANon-phased studies
8(4.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

60 of 75 finished

Non-Completion Rate

20.0%

15 ended early

Currently Active

80

trials recruiting

Total Trials

175

all time

Status Distribution
Active(92)
Completed(60)
Terminated(15)
Other(8)

Detailed Status

Completed60
Recruiting58
Active, not recruiting22
Not yet recruiting11
Withdrawn11
unknown8

Development Timeline

Analytics

Development Status

Total Trials
175
Active
80
Success Rate
93.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 113 (7.5%)
Phase 164 (37.0%)
Phase 281 (46.8%)
Phase 37 (4.0%)
N/A8 (4.6%)

Trials by Status

enrolling_by_invitation11%
not_yet_recruiting116%
withdrawn116%
recruiting5833%
terminated42%
completed6034%
active_not_recruiting2213%
unknown85%

Recent Activity

Clinical Trials (175)

Showing 20 of 175 trialsScroll for more
NCT07721467Phase 2

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

Not Yet Recruiting
NCT07610135Phase 1

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Recruiting
NCT07332143Phase 2

Psilocybin-Assisted Therapy

Recruiting
NCT07360301Phase 1

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Not Yet Recruiting
NCT06299319Phase 1

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Completed
NCT07296094Phase 2

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

Not Yet Recruiting
NCT07833761Phase 1

ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder

Not Yet Recruiting
NCT07607938Phase 1

Psilocybin as a Novel Therapy for Residual Anhedonia

Recruiting
NCT07565493Early Phase 1

Psilocybin Administration With 5-HT1a Blockade

Recruiting
NCT06200155Phase 2

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Recruiting
NCT06615908Phase 1

Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy

Recruiting
NCT06885996Phase 2

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

Not Yet Recruiting
NCT04123314Early Phase 1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Recruiting
NCT06355414Phase 1

Psilocybin in Chronic Low Back Pain and Depression

Recruiting
NCT06430541Phase 1

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Recruiting
NCT05546658Early Phase 1

Effects of Psilocybin in Obsessive Compulsive Disorder

Active Not Recruiting
NCT06989957Phase 1

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Recruiting
NCT06349083Phase 2

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Recruiting
NCT07211438Phase 2

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Recruiting
NCT05220046Phase 1

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
175